The PPARγ agonist pioglitazone crosses the blood–brain barrier and reduces tumor growth in a human xenograft model
2013
Purpose
The peroxisome proliferator-activated receptor gamma (PPARγ), a member of the nuclear hormone receptor family, represents a target in glioma therapy due to its antineoplastic effects in vitro on human glioma cell lines. We investigate the antineoplastic effects of the PPARγ agonist pioglitazone (pio) in a human glioma xenograft model to define the minimal required dose to induce antineoplastic effects. Additionally, we assess the ability of pio to cross the blood–brain barrier by measuring brain parenchymal concentration after oral administration.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
22
References
39
Citations
NaN
KQI